stella
beta
HALOS: A Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of Multiple Ascending Doses of ION582 in Participants With Angelman Syndrome — Stella
Recruiting
Back to Angelman Syndrome trials
Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations
(11 sites)
United States
Rady Children's Hospital, San Diego, California
Colorado Children's Hospital Research Institute, Aurora, Colorado
Rush University Medical Center, Chicago, Illinois
Boston Children's Hospital, Boston, Massachusetts
University of North Carolina at Chapel Hill School of Medicine, Carrboro, North Carolina
Show all 11 locations
View full record on ClinicalTrials.gov